• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

BioNTech to buy Biotheus, gaining control of cancer bispecific

cafead

Administrator
Staff member
  • cafead   Nov 13, 2024 at 11:42: AM
via Biotheus’ antibody drug targets PD-L1 and VEGF, a similar design as Summit Therapeutics’ Keytruda-beating ivonescimab.

article source